Filing Details

Accession Number:
0001209191-21-008750
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-02-09 15:29:44
Reporting Period:
2021-02-09
Accepted Time:
2021-02-09 15:29:44
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1641281 Bolt Biotherapeutics Inc. BOLT () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1245624 James Healy C/o Bolt Biotherapeutics, Inc.
900 Chesapeake Drive
Redwood City CA 94063
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-02-09 1,104,209 $0.00 1,104,209 No 4 C Indirect By Sofinnova Venture Partners X, L.P.
Common Stock Acquisiton 2021-02-09 1,200,228 $0.00 2,304,437 No 4 C Indirect By Sofinnova Venture Partners X, L.P.
Common Stock Acquisiton 2021-02-09 450,000 $20.00 2,754,437 No 4 P Indirect By Sofinnova Venture Partners X, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect By Sofinnova Venture Partners X, L.P.
No 4 C Indirect By Sofinnova Venture Partners X, L.P.
No 4 P Indirect By Sofinnova Venture Partners X, L.P.
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series C-1 Preferred Stock Disposition 2021-02-09 1,104,209 $0.00 1,104,209 $0.00
Common Stock Series C-2 Preferred Stock Disposition 2021-02-09 1,200,228 $0.00 1,200,228 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the "IPO") and had no expiration date.
  2. The securities reported herein are held of record by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X. The Reporting Person is one of three managing members of SM X and may be deemed to have shared voting and dispositive power over the shares held by SVP X. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein.
  3. The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date.